A clinical trial to study effects of oral and long acting injectable antipsychotic in patients with schizophrenia.
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2020/02/023446
- Lead Sponsor
- Government Medical College and Hospital Chandigarh Sector
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1)Patients diagnosed with schizophrenia as per DSM-5
2)Total duration of illness shall be less than one year.
3)Age of the patients shall be between 18-45 years.
4)Drug naïve or not on any psycho tropics for 2 weeks.
5)Patients willing to participate and give consent or in case the patient lacks mental capacity, his/her nominated representative gives consent to participate.
1)Patients who are not willing to give consent.
2)Pregnant and breast feeding patients.
3)Patients with co-morbid psychiatric illness and substance dependence.
4)Patients with severe medical and surgical illness.
5)Patients with high suicidal risk( Beckâ??s scale for suicidal ideation score >29)
6)Patients with history of sensitivity to haloperidol in the past.
7)Patients with history of depot antipsychotic administration in the past.
8)Patients with no response to haloperidol in the past or those reporting non-tolerability to the drug in the past.
9)Patients who had received ECT in the past.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy and safety profile of oral and long acting injectable haloperidol in patients with first episode schizophrenia.Timepoint: Baseline, week 2, week 4, week 6, week 8, week 12
- Secondary Outcome Measures
Name Time Method To compare quality of life in patients with first episode schizophrenia on oral and long acting injectable haloperidol. <br/ ><br> <br/ ><br>Timepoint: Baseline, week 4, week8, week 12